ATE400261T1 - Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie - Google Patents

Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie

Info

Publication number
ATE400261T1
ATE400261T1 AT04005807T AT04005807T ATE400261T1 AT E400261 T1 ATE400261 T1 AT E400261T1 AT 04005807 T AT04005807 T AT 04005807T AT 04005807 T AT04005807 T AT 04005807T AT E400261 T1 ATE400261 T1 AT E400261T1
Authority
AT
Austria
Prior art keywords
image
radiotherapy
chemotherapy
tumor
histone deacetylase
Prior art date
Application number
AT04005807T
Other languages
English (en)
Inventor
Yih-Lin Chung
Original Assignee
Asan Lab Company Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asan Lab Company Cayman Ltd filed Critical Asan Lab Company Cayman Ltd
Application granted granted Critical
Publication of ATE400261T1 publication Critical patent/ATE400261T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04005807T 2004-03-11 2004-03-11 Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie ATE400261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04005807A EP1574213B1 (de) 2004-03-11 2004-03-11 Verwendung von Histone Deacetylase Hemmern zur Steigerung der therapeutischen Wirkung in der Radiotherapie und Chemotherapie

Publications (1)

Publication Number Publication Date
ATE400261T1 true ATE400261T1 (de) 2008-07-15

Family

ID=34814300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04005807T ATE400261T1 (de) 2004-03-11 2004-03-11 Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie

Country Status (4)

Country Link
EP (1) EP1574213B1 (de)
AT (1) ATE400261T1 (de)
DE (1) DE602004014895D1 (de)
ES (1) ES2311763T3 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272497B2 (en) * 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
WO2008003013A2 (en) * 2006-06-29 2008-01-03 Abbott Laboratories Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
WO2008132233A1 (en) * 2007-05-01 2008-11-06 Kuros Biosurgery Ag Composition, methods and kits for prevention of adhesion
EP2237684A2 (de) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonisten für antimikrobielle peptidsysteme
EP2445533B1 (de) * 2009-06-26 2017-02-08 Sunny Pharmtech Inc., Verfahren zur behandlung bzw. linderung von schleimhaut- oder augentoxizitäten
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
EP2698156A1 (de) * 2012-08-16 2014-02-19 Lunamed AG Phenylbutyrensäure zur Chemoprävention
KR101482086B1 (ko) * 2012-11-13 2015-01-13 인하대학교 산학협력단 히스톤 탈아세틸화효소 2의 억제제를 유효성분으로 포함하는 페이로니병의 예방 또는 치료용 조성물
CN104414967A (zh) * 2013-09-06 2015-03-18 康普药业股份有限公司 一种更昔洛韦注射液及其制备方法
US10729669B2 (en) * 2015-07-28 2020-08-04 University Of Iowa Research Foundation Compositions and methods for treating cancer
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
AU2018255269B2 (en) 2017-04-17 2023-03-09 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037376A (en) * 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6538030B2 (en) * 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
GB2389365A (en) * 2001-01-12 2003-12-10 Methylgene Inc Methods for specifically inhibiting histone deacetylase-4
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome

Also Published As

Publication number Publication date
DE602004014895D1 (de) 2008-08-21
EP1574213A1 (de) 2005-09-14
EP1574213B1 (de) 2008-07-09
ES2311763T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
ATE400261T1 (de) Verwendung von histone deacetylase hemmern zur steigerung der therapeutischen wirkung in der radiotherapie und chemotherapie
CL2021002002A1 (es) Inhibidores de enpp1 y métodos para modular una respuesta inmunitaria.
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
UY28310A1 (es) Pirazoles como inhibidores de factor de necrosis tumoral
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
DE602004019229D1 (de) Inhibitoren von mitotischem kinesin
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
NO20050198D0 (no) Mitotiske kinesininhibitorer
MX2025013001A (es) Inhibidores espiro-heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos.
RU2013131004A (ru) Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
EA201691336A1 (ru) Способ лечения фибрилляции предсердий
RU2008124827A (ru) Лечение нейроэндокринных опухолей
MX2021010560A (es) Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
MX2021011760A (es) Metodos para el tratamiento de canceres usando antisentido.
WO2007070372A3 (en) Compositions and methods for inhibiting cellular proliferation
MX2025005713A (es) Moduladores basados en ftalazinona para el tratamiento de enfermedad
NO20061319L (no) 5-arylpyrimidiner som anticancer legemidler
MX2024012937A (es) Inhibidores del receptor del factor de crecimiento epidérmico en el tratamiento de cáncer
Yavas et al. The effect of Halofuginone in the amelioration of radiation induced-lung fibrosis
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
Garden Mucositis: current management and investigations
WO2023164455A3 (en) Compositions and methods to modulate the immune system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties